Formulation Development and Evaluation of Celecoxib Niosomes

Author(s): M. Sunitha Reddy*, Bommakuri Swetha and Anie Vijetha

Abstract: The present study deals with formulation development and evaluation of celecoxib niosomes with main aim of enhancing bioavailability and therapeutic activity over a longer period of time. Niosomes are non-ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or their lipids. These Niosomes can entrap both hydrophilic and lipophilic drugs and can prolong the circulation of the entrapped drug in body. body. Encapsulation of drug in vesicular system can predict prolong existence of drug in the systemic circulation and enhance penetration into the target tissue, perhaps reduce toxicity if selective uptake can be achieved. Celecoxib is a NSAID, highly selective cyclooxagenase-2 (COX-2) inhibitor, which is used for treating rheumatoid arthritis, osteoarthritis and acute pain. In the present study celecoxib Niosomes were prepared by thin-film hydration method using different concentrations of Tween 80 or span 80, cholesterol. All the formulation was characterized using differential scanning calorimetry, vesicle size, zeta potential, stability studies, entrapment efficiency. The vesicle size range of celecoxib Niosomes were found to 209-322nm. The invitro release studies revealed that most celecoxib Niosomal formulations released more than 90% of its drug content within 48 hours. Accelerated stability studies were done for about 1month according to ICH guidelines for optimized formulation.

PAGES: 144-157  |  262 VIEWS  238 DOWNLOADS